Scott Martin

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Identification of Hepatitis C Virus NS5A Inhibitors

Julie A. Lemm, Donald R. O’Boyle, Mengping Liu et al. · Journal of Virology · 2009 · 194 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

Paul A. Dickinson, Mireille Cantarini, J. Collier et al. · Drug Metabolism and Disposition · 2016 · 129 citations

Medicine, Pharmacokinetics, Pharmacology +17

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Robert G. Gentles, Min Ding, John A. Bender et al. · Journal of Medicinal Chemistry · 2014 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17